Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 3
1992 1
1993 2
1994 2
1996 8
1997 1
1998 5
1999 8
2000 7
2001 4
2002 4
2003 5
2004 3
2005 5
2006 5
2007 7
2008 7
2009 9
2010 7
2011 11
2012 14
2013 5
2014 10
2015 11
2016 16
2017 19
2018 13
2019 20
2020 295
2021 179
Text availability
Article attribute
Article type
Publication date

Search Results

615 results
Results by year
Filters applied: . Clear all
Page 1
Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID-19.
Damle B, Vourvahis M, Wang E, Leaney J, Corrigan B. Damle B, et al. Clin Pharmacol Ther. 2020 Aug;108(2):201-211. doi: 10.1002/cpt.1857. Epub 2020 May 12. Clin Pharmacol Ther. 2020. PMID: 32302411 Free PMC article. Review.
Azithromycin (AZ) is a broad-spectrum macrolide antibiotic with a long half-life and a large volume of distribution. ...It is essential that the clinical pharmacology (CP) characteristics of AZ be considered in planning and conducting clinical trials of AZ alone or in comb
Azithromycin (AZ) is a broad-spectrum macrolide antibiotic with a long half-life and a large volume of distribution. ...It is essenti
Azithromycin in the treatment of COVID-19: a review.
Echeverría-Esnal D, Martin-Ontiyuelo C, Navarrete-Rouco ME, De-Antonio Cuscó M, Ferrández O, Horcajada JP, Grau S. Echeverría-Esnal D, et al. Expert Rev Anti Infect Ther. 2021 Feb;19(2):147-163. doi: 10.1080/14787210.2020.1813024. Epub 2020 Oct 6. Expert Rev Anti Infect Ther. 2021. PMID: 32853038 Review.
INTRODUCTION: SARS-CoV-2 is a novel virus that causes coronavirus disease-19 (COVID-19). Antiviral and immunomodulatory agents have been proposed as potential treatments. Azithromycin exhibits both properties and therefore may play a role. ...
INTRODUCTION: SARS-CoV-2 is a novel virus that causes coronavirus disease-19 (COVID-19). Antiviral and immunomodulatory agents
Macrolides and viral infections: focus on azithromycin in COVID-19 pathology.
Pani A, Lauriola M, Romandini A, Scaglione F. Pani A, et al. Int J Antimicrob Agents. 2020 Aug;56(2):106053. doi: 10.1016/j.ijantimicag.2020.106053. Epub 2020 Jun 10. Int J Antimicrob Agents. 2020. PMID: 32534189 Free PMC article. Review.
Since the most severe clinical manifestation of COVID-19 appears to be a severe acute respiratory syndrome, azithromycin has been proposed as a potential treatment. Azithromycin is known to have immunomodulating and antiviral properties. ...Furthermore, there …
Since the most severe clinical manifestation of COVID-19 appears to be a severe acute respiratory syndrome, azithromycin has been pro …
Azithromycin: The First Broad-spectrum Therapeutic.
Firth A, Prathapan P. Firth A, et al. Eur J Med Chem. 2020 Dec 1;207:112739. doi: 10.1016/j.ejmech.2020.112739. Epub 2020 Aug 19. Eur J Med Chem. 2020. PMID: 32871342 Free PMC article. Review.
Azithromycin is one such broad-spectrum therapeutic that is both included in the University of Oxford's RECOVERY and excluded from the World Health Organization's SOLIDARITY trials. Here we review azithromycin's broad antibiotic, antimalarial,
Azithromycin is one such broad-spectrum therapeutic that is both included in the University of Oxford's RECOVERY and excluded
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19.
Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, Avezum A, Damiani LP, Marcadenti A, Kawano-Dourado L, Lisboa T, Junqueira DLM, de Barros E Silva PGM, Tramujas L, Abreu-Silva EO, Laranjeira LN, Soares AT, Echenique LS, Pereira AJ, Freitas FGR, Gebara OCE, Dantas VCS, Furtado RHM, Milan EP, Golin NA, Cardoso FF, Maia IS, Hoffmann Filho CR, Kormann APM, Amazonas RB, Bocchi de Oliveira MF, Serpa-Neto A, Falavigna M, Lopes RD, Machado FR, Berwanger O; Coalition Covid-19 Brazil I Investigators. Cavalcanti AB, et al. N Engl J Med. 2020 Nov 19;383(21):2041-2052. doi: 10.1056/NEJMoa2019014. Epub 2020 Jul 23. N Engl J Med. 2020. PMID: 32706953 Free PMC article. Clinical Trial.
BACKGROUND: Hydroxychloroquine and azithromycin have been used to treat patients with coronavirus disease 2019 (Covid-19). ...CONCLUSIONS: Among patients hospitalized with mild-to-moderate Covid-19, the use of hydroxychloroquine, alone or with azithromycin, did not …
BACKGROUND: Hydroxychloroquine and azithromycin have been used to treat patients with coronavirus disease 2019 (Covid-19). ...CONCLUS …
Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.
Fantini J, Chahinian H, Yahi N. Fantini J, et al. Int J Antimicrob Agents. 2020 Aug;56(2):106020. doi: 10.1016/j.ijantimicag.2020.106020. Epub 2020 May 13. Int J Antimicrob Agents. 2020. PMID: 32405156 Free PMC article.
The emergence of SARS-coronavirus-2 (SARS-CoV-2) has led to a global pandemic disease referred to as coronavirus disease 19 (COVID-19). Hydroxychloroquine (CLQ-OH)/azithromycin (ATM) combination therapy is currently being tested for the treatment of COVID-19, with promisin …
The emergence of SARS-coronavirus-2 (SARS-CoV-2) has led to a global pandemic disease referred to as coronavirus disease 19 (COVID-19). Hydr …
Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical Evidence and Prescribing Guidelines.
Sultana J, Cutroneo PM, Crisafulli S, Puglisi G, Caramori G, Trifirò G. Sultana J, et al. Drug Saf. 2020 Aug;43(8):691-698. doi: 10.1007/s40264-020-00976-7. Drug Saf. 2020. PMID: 32696429 Free PMC article. Review.
The global COVID-19 pandemic has led to a race to find medications that can improve the prognosis of the disease. Azithromycin, in association with hydroxychloroquine or chloroquine, has been proposed as one such medication. The aim of this review is to describe the pharma …
The global COVID-19 pandemic has led to a race to find medications that can improve the prognosis of the disease. Azithromycin, in as …
Azithromycin in viral infections.
Oliver ME, Hinks TSC. Oliver ME, et al. Rev Med Virol. 2021 Mar;31(2):e2163. doi: 10.1002/rmv.2163. Epub 2020 Sep 23. Rev Med Virol. 2021. PMID: 32969125 Free PMC article. Review.
Azithromycin (AZM) is a synthetic macrolide antibiotic effective against a broad range of bacterial and mycobacterial infections. ...
Azithromycin (AZM) is a synthetic macrolide antibiotic effective against a broad range of bacterial and mycobacterial infections. ...
615 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page